Mark Rosenblum Net Worth

The estimated Net Worth of Mark J Rosenblum is at least $676 Tisíc dollars as of 31 May 2022. Mr. Rosenblum owns over 28,000 units of Salarius Pharmaceuticals stock worth over $237,310 and over the last 14 years he sold SLRX stock worth over $0. In addition, he makes $438,287 as Chief Financial Officer a Executive Vice President - Finance at Salarius Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Rosenblum SLRX stock SEC Form 4 insiders trading

Mark has made over 6 trades of the Salarius Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 28,000 units of SLRX stock worth $5,040 on 31 May 2022.

The largest trade he's ever made was buying 76,246 units of Salarius Pharmaceuticals stock on 3 March 2022 worth over $29,736. On average, Mark trades about 4,933 units every 121 days since 2010. As of 31 May 2022 he still owns at least 148,319 units of Salarius Pharmaceuticals stock.

You can see the complete history of Mr. Rosenblum stock trades at the bottom of the page.

Mark Rosenblum biography

Mark J. Rosenblum serves as Chief Financial Officer, Executive Vice President - Finance of the Company. Mr. Rosenblum has served as our Executive Vice President Finance and Chief Financial Officer since September 2019. Prior to September 2019, Mr. Rosenblum served as a financial consultant to Private Salarius since February 2019, to assist in the Merger. Prior to joining Private Salarius, Mr. Rosenblum served as chairman, chief executive officer and a director of ActiveCare, Inc. (Nasdaq: ACAR), a healthcare company, from December 2017 to March 2019. Mr. Rosenblum worked as a financial consultant for various companies from 2014 to 2017. Prior to that, Mr. Rosenblum served as the chief financial officer of Advaxis, Inc. (Nasdaq: ADXS), a biotechnology company, from January 2010 to April 2014. From 1985 through 2003, Mr. Rosenblum was employed by Wellman, Inc., a global public chemical manufacturer, which was subsequently acquired by DAK Americas, serving in various capacities including chief accounting officer. Mr. Rosenblum holds both a Masters in Accountancy and a B.S. degree in Accounting from the University of South Carolina. Mr. Rosenblum began his career in 1977 with Haskins & Sells, CPA (currently known as Deloitte), was a licensed Certified Public Accountant for over 30 years, and is currently a member of the American Institute of Certified Public Accountants.

What is the salary of Mark Rosenblum?

As the Chief Financial Officer a Executive Vice President - Finance of Salarius Pharmaceuticals, the total compensation of Mark Rosenblum at Salarius Pharmaceuticals is $438,287. There are 3 executives at Salarius Pharmaceuticals getting paid more, with William McVicar having the highest compensation of $1,160,520.

How old is Mark Rosenblum?

Mark Rosenblum is 66, he's been the Chief Financial Officer a Executive Vice President - Finance of Salarius Pharmaceuticals since 2019. There are 2 older and 6 younger executives at Salarius Pharmaceuticals. The oldest executive at Salarius Pharmaceuticals, Inc. is Arnold Hanish, 72, who is the Independent Director.

What's Mark Rosenblum's mailing address?

Mark's mailing address filed with the SEC is C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE X, HOUSTON, TX, 77021.

Insiders trading at Salarius Pharmaceuticals

Over the last 5 years, insiders at Salarius Pharmaceuticals have traded over $0 worth of Salarius Pharmaceuticals stock and bought 487,662 units worth $209,636 . The most active insiders traders include David J. Arthur, Mark J Rosenblum a Arnold C Hanish. On average, Salarius Pharmaceuticals executives and independent directors trade stock every 40 days with the average trade being worth of $33,925. The most recent stock trade was executed by Tess Burleson on 7 June 2022, trading 27,700 units of SLRX stock currently worth $4,986.

What does Salarius Pharmaceuticals do?

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

Complete history of Mr. Rosenblum stock trades at Ayala Pharmaceuticals a Salarius Pharmaceuticals

Salarius Pharmaceuticals executives and stock owners

Salarius Pharmaceuticals executives and other stock owners filed with the SEC include:

• William McVicar,
  Chairman of the Board
• David J. Arthur M.B.A.,
  CEO, Pres & Director
• David Arthur,
  President, Chief Executive Officer, Director
• Mark Rosenblum,
  Chief Financial Officer, Executive Vice President - Finance
• Mark J. Rosenblum,
  Exec. VP of Fin. & CFO
• Maureen McEnroe,
  IR Contact Officer
• Jonathan Lieber,
  Independent Director
• Arnold Hanish,
  Independent Director
• Tess Burleson,
  Independent Director
• Paul Lammers,
  Lead Independent Director
• Bruce McCreedy,
  Interim Chief Scientific Officer and Director
• Nadeem Mirza,
  Senior Vice President - Clinical Development
• Dr. Daniela Y. Santiesteban,
  Director of Research and Bus. Devel.
• Dr. Nadeem Q. Mirza M.D., M.P.H.,
  Sr. VP of Clinical Devel.
• Jonathan P Northrup,
  Director
• Pao Yu Chuang,
  Controller
• Scott Jordan,
  Chief Financial Officer